Data published at a virtual Clinical Trial Session, conducted by the Muscular Dystrophy Association (MDA), show Zolgensma (onasemnogene abeparvovec-xioi) produced significant benefit to people with spinal muscular atrophy (SMA).
The data, which are drawn from a range of studies, are being presented virtually after the 2020 MDA Annual Conference was cancelled, due to the recent COVID-19 outbreak.
Novartis (NOVN: VX) company AveXis presented the data, which includes patients treated pre-symptomatically, and showed sustained durability in patients now up to five years post-dosing and some patients more than five years of age.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze